Electrocardiographic method for identifying drug-induced repolarization abnormalities associated with a reduction of the rapidly activating delayed rectifier potassium current.
Several important non-cardiac drugs have been removed from the market after revealing harmful effect that was not identified during prior safety-assessment studies. We developed a new technique for the measurements of repolarization abnormalities from surface ECGs; this method improves sensitivity and specificity of the current technique used to identify the presence of abnormal ion current kinetics in the myocardial cells namely a prolongation of the QT interval on the surface ECG signal. We described in this paper the method and preliminary results, revealing the superiority of our technique that may play a role in the future of drug-safety assessment.
Couderc
J P
JP
Rochester Univ., NY 14642, USA. heartjpc@heart.rochester.edu
Vaglio
M
M
Xia
X
X
McNitt
S
S
Hyrien
O
O
D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000503:physiopathology*; D001372:Aza Compounds / Q000009:adverse effects*; D051668:Delayed Rectifier Potassium Channels / Q000187:drug effects / Q000502:physiology*; D004562:Electrocardiography / Q000379:methods*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000503:physiopathology; D008297:Male; D000077266:Moxifloxacin; D010919:Placebos; D011804:Quinolines / Q000009:adverse effects*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D051668:Delayed Rectifier Potassium Channels; D024841:Fluoroquinolones; D010919:Placebos; D011804:Quinolines; D000077266:Moxifloxacin